Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/10/2019
SIETES contiene 92829 citas

 
 
 1 a 7 de 7 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLOS Medicine 2017:10 de octubre. [Ref.ID 102114]
2.Tiene citas relacionadas
Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. The authors reply. N Engl J Med 2013;369:2459. [Ref.ID 96682]
3.Tiene citas relacionadas
Vandecasteele SJ, De Vriese AS. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458-9. [Ref.ID 96681]
4.Tiene citas relacionadas Cita con resumen
Cherney D, Maahs DM. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458. [Ref.ID 96680]
5.Tiene citas relacionadas Cita con resumen
Tavares Jr AR. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2457-8. [Ref.ID 96679]
6.Tiene citas relacionadas
Ingelfinger JR, Marsden PA. Estimated GFR and risk of death - Is cystatin C useful?. N Engl J Med 2013;369:974-5. [Ref.ID 96071]
7.Tiene citas relacionadas Cita con resumen
Shlipak MG, Mathushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey AS, Gansevoort RT, for the CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369:932-43. [Ref.ID 96070]
Seleccionar todas
 
 1 a 7 de 7